Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 19, 2020updated 26 May 2020 11:54am

International study to assess chloroquine to prevent Covid-19

An international group of researchers is conducting a clinical trial to assess antimalaria drug chloroquine for preventing Covid-19 or reducing its severity in front-line healthcare workers.

An international group of researchers is conducting a clinical trial to assess antimalaria drug chloroquine for preventing Covid-19 or reducing its severity in front-line healthcare workers.

The research group, named COVID-19 Research Outcomes Worldwide Network (CROWN), aims to investigate different therapies for the disease.

Chloroquine is being evaluated in the CROWN CORONATION trial, which is being conducted from Washington University School of Medicine in St Louis, Missouri, US.

Washington University School of Medicine is the clinical coordinating centre for the international trial, which is co-led by collaborators from University College London and Wits in South Africa.

Washington University anesthesiology department professor and head Michael Avidan said: “Because of their repeated close contacts with infected patients, front-line health-care workers in all parts of the world have a higher risk of contracting Covid-19 than most members of the general public.

“In some places, more than 10% of those who have become infected are health-care workers. There is an urgent need to identify drugs that are effective at preventing infection or mitigating its severity.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

CROWN CORONATION will be a large-scale study that will enrol nearly 30,000 front-line healthcare workers worldwide, including in lower and middle-income countries. It will assess three unique dose schedules of chloroquine in healthy participants.

The trial aims to study the drug’s ability to prevent Covid-19 infection in healthcare workers or mitigate the disease severity in infected people.  Researchers also intend to establish the lowest dose that could provide a benefit.

Avidan added: “When people have to travel to parts of the world where malaria is a problem, they often take low doses of chloroquine to help prevent infection.

“We want to learn whether this drug might work in a similar fashion in the case of Covid-19, or at the very least, whether low-dose chloroquine might help prevent the severe and life-threatening complications associated with the illness.”

The trial will run for five months and obtained data will be compiled at University College London.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU